CureVac N.V [CVAC] vs Nurix Therapeutics [NRIX] Detailed Stock Comparison

CureVac N.V.

NASDAQ
Loading...

Nurix Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: CureVac N.V. wins in 14 metrics, Nurix Therapeutics Inc. wins in 3 metrics, with 0 ties. CureVac N.V. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric CureVac N.V. Nurix Therapeutics Inc. Better
P/E Ratio (TTM) 6.96 N/A N/A
Price-to-Book Ratio 0.83 3.53 CureVac N.V.
Debt-to-Equity Ratio 4.03 12.20 CureVac N.V.
PEG Ratio -0.35 -5.75 CureVac N.V.
EV/EBITDA 2.39 -3.96 CureVac N.V.
Profit Margin (TTM) 182.11% 0.00% CureVac N.V.
Operating Margin (TTM) 573.04% -1,479.45% CureVac N.V.
EBITDA Margin (TTM) 573.04% N/A N/A
Return on Equity 23.28% -61.40% CureVac N.V.
Return on Assets (TTM) 20.20% -31.50% CureVac N.V.
Free Cash Flow (TTM) $96.80M $-263.47M CureVac N.V.
1-Year Return 10.69% 67.07% Nurix Therapeutics Inc.
Price-to-Sales Ratio (TTM) 14.83 23.68 CureVac N.V.
Enterprise Value $537.57M $1.22B Nurix Therapeutics Inc.
EV/Revenue Ratio 6.53 16.97 CureVac N.V.
Gross Profit Margin (TTM) 99.31% N/A N/A
Revenue per Share (TTM) $0 $1 Nurix Therapeutics Inc.
Earnings per Share (Diluted) $0.67 $-3.17 CureVac N.V.
Beta (Stock Volatility) 1.84 1.98 CureVac N.V.
Short % of Float 0.49% 17.73% CureVac N.V.

CureVac N.V. vs Nurix Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

CVAC
NRIX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
CureVac N.V.0.00%4.02%-10.56%-13.86%-13.86%-0.21%
Nurix Therapeutics Inc.-5.44%-11.39%-8.56%-2.09%-8.02%-14.29%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
CureVac N.V.10.69%-54.49%-95.36%-91.66%-91.66%-91.66%
Nurix Therapeutics Inc.67.07%62.64%-39.51%-6.58%-6.58%-6.58%

Performance & Financial Health Analysis: CureVac N.V. vs Nurix Therapeutics Inc.

MetricCVACNRIX
Market Information
Market Cap i$1.05B$1.71B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,241,6611,143,118
90 Day Avg. Volume i1,688,6771,318,446
Last Close$4.66$15.48
52 Week Range$4.00 - $5.55$8.19 - $22.50
% from 52W High-16.04%-31.20%
All-Time High$151.80 (Dec 07, 2020)$52.38 (Dec 14, 2020)
% from All-Time High-96.93%-70.45%
Growth Metrics
Quarterly Revenue Growth-0.89%-0.66%
Quarterly Earnings Growth-0.19%-0.66%
Financial Health
Profit Margin (TTM) i1.82%0.00%
Operating Margin (TTM) i5.73%-14.79%
Return on Equity (TTM) i0.23%-0.61%
Debt to Equity (MRQ) i4.0312.20
Cash & Liquidity
Book Value per Share (MRQ)$5.63$4.65
Cash per Share (MRQ)$2.30$5.23
Operating Cash Flow (TTM) i$-139,731,344$-260,292,000
Levered Free Cash Flow (TTM) i$188.64M$-145,462,624
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: CureVac N.V. vs Nurix Therapeutics Inc.

MetricCVAC (Jan 20, 2026)NRIX (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i6.96N/A
Forward P/E i-8.02-5.75
PEG Ratio i-0.35-5.75
Price to Sales (TTM) i14.8323.68
Price to Book (MRQ) i0.833.53
Market Capitalization
Market Capitalization i$1.05B$1.71B
Enterprise Value i$537.57M$1.22B
Enterprise Value Metrics
Enterprise to Revenue i6.5316.97
Enterprise to EBITDA i2.39-3.96
Risk & Other Metrics
Beta i1.841.98
Book Value per Share (MRQ) i$5.63$4.65

Financial Statements Comparison: CureVac N.V. vs Nurix Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCVAC (2024)NRIX (2025)
Revenue/Sales i621.09M83.98M
Cost of Goods Sold i122.82MN/A
COGS % of Revenue i19.8%0.0%
Gross Profit i498.27MN/A
Gross Margin i80.2%0.0%
Research & Development i177.60M316.90M
Operating Income (EBIT) i206.20M-285.67M
Operating Margin i33.2%-340.2%
EBITDA i242.37M-266.81M
EBITDA Margin i39.0%-317.7%
Pre-Tax Income i221.52M-263.70M
Pre-Tax Income % of Revenue i35.7%-314.0%
Income Tax i33.30M760,000
Income Tax % of Revenue i5.4%0.9%
Net Income (Profit) i188.22M-264.46M
Profit Margin i30.3%-314.9%

Balance Sheet & Liquidity Metrics

MetricCVAC (2024)NRIX (2025)
Cash & Equivalents i559.08M246.96M
Total Current Assets i610.91M606.82M
Total Current Assets % of Revenue i98.4%722.6%
Total Current Liabilities i83.96M86.47M
Total Current Liabilities % of Revenue i13.5%103.0%
Long-Term Debt i39.04M52.91M
Long-Term Debt % of Revenue i6.3%63.0%
Total Shareholders Equity i808.43M538.75M
Retained Earnings i-1.63B-1.00B
Retained Earnings % of Revenue i-262.3%-1,194.6%
Property, Plant & Equipment i1.85M94.09M

Cash Flow Statement Comparison

MetricCVAC (2024)NRIX (2025)
Operating Cash Flow i42.53M-250.31M
Operating Cash Flow % of Revenue i6.8%-298.1%
Capital Expenditures i-16.61M-14.00M
Free Cash Flow i96.80M-263.47M
FCF Margin i15.6%-313.7%
Debt Repayment i-5.93MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricCVACNRIX
Shares Short i547,31618.13M
Short Ratio i0.3214.56
Short % of Float i0.49%17.73%
Shares Outstanding i225.17M103.40M
Float Shares i180.77M87.14M
% Held by Insiders i0.10%1.10%
% Held by Institutions i10.43%110.89%
% Held by Public i89.47%-11.99%

Dividend Analysis & Yield Comparison: CureVac N.V. vs Nurix Therapeutics Inc.

MetricCVACNRIX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A